Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 3856Neoplasms 2988Prostatic Neoplasms 1751Colorectal Neoplasms 1426Lung Neoplasms 1327Motor Activity 802Head and Neck Neoplasms 683Pancreatic Neoplasms 662Colonic Neoplasms 655Uterine Cervical Neoplasms 648Carcinoma, Non-Small-Cell Lung 629Carcinoma, Hepatocellular 628Rectal Neoplasms 569Stomach Neoplasms 544Brain Neoplasms 483Ovarian Neoplasms 438Anxiety Disorders 419Pain 418Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 374Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 339Melanoma 322Multiple Myeloma 320Lymphoma 305Depression 305Endometrial Neoplasms 289Liver Neoplasms 279

Interventions

Radiotherapy 2Immune Checkpoint Inhibitors 2aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Interventional × Advanced NSCLC × Clear all
NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Allist Pharmaceuticals, Inc.

Phase NA Terminated
116 enrolled
Thoracic

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡